As a Managing Director of Diaceutics, Jordan leads the client projects to ensure the Diaceutics Method® is harnessed to deliver maximum strategic and critical thinking, and leverage the diagnostic in support of targeted therapies. He has worked on over 20 targeted therapies, optimizing diagnostics into a supportive environment for precision medicine.
Jordan has academic and professional qualifications in biomedical and clinical sciences. He is a state licensed scientist in hematology, spending five years at Cambridge University diagnosing cancer patients and working to aid their care. Jordan is renowned for biomarker testing through his role at UK NEQAS, one of the largest proficiency test providers, where he founded seven new quality programs, including the first for FLT3 and NPM1, which involved engaging with 200 AML diagnostic laboratories globally.